In a highly competitive market, some sponsors are alienating sites and investigators by wasting their time. To reduce the burden on sites, sponsors must rethink how they manage safety reporting.
Of course, investigators must be kept informed of safety issues throughout the trial, but inundating them with
unnecessary and duplicative reports is counterproductive.
It’s a costly problem with profound implications for compliance, site relations and patient safety. In a recent WCG
webinar, Elena Jouravleva, PhD, Director of Regulatory for US Oncology Network, and Steven Beales, WCG’s Senior
Vice President, Scientific and Regulatory, discussed these issues, with particular emphasis on the burden placed on